HUMA vs. EVLV, DSKE, BARK, SST, BODY, SWTX, APGE, IOVA, ACLX, and DNLI
Should you be buying Humacyte stock or one of its competitors? The main competitors of Humacyte include Evolv Technologies (EVLV), Daseke (DSKE), BARK (BARK), System1 (SST), Beachbody (BODY), SpringWorks Therapeutics (SWTX), Apogee Therapeutics (APGE), Iovance Biotherapeutics (IOVA), Arcellx (ACLX), and Denali Therapeutics (DNLI).
Evolv Technologies (NASDAQ:EVLV) and Humacyte (NASDAQ:HUMA) are both small-cap computer and technology companies, but which is the better stock? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, community ranking, valuation, profitability, risk, earnings, dividends and media sentiment.
Evolv Technologies has a beta of 1.37, meaning that its share price is 37% more volatile than the S&P 500. Comparatively, Humacyte has a beta of 1.27, meaning that its share price is 27% more volatile than the S&P 500.
In the previous week, Humacyte had 3 more articles in the media than Evolv Technologies. MarketBeat recorded 8 mentions for Humacyte and 5 mentions for Evolv Technologies. Humacyte's average media sentiment score of 0.95 beat Evolv Technologies' score of 0.80 indicating that Evolv Technologies is being referred to more favorably in the media.
Evolv Technologies has higher revenue and earnings than Humacyte. Humacyte is trading at a lower price-to-earnings ratio than Evolv Technologies, indicating that it is currently the more affordable of the two stocks.
Humacyte has a net margin of 0.00% compared to Humacyte's net margin of -106.93%. Humacyte's return on equity of -45.57% beat Evolv Technologies' return on equity.
Evolv Technologies presently has a consensus price target of $5.65, indicating a potential upside of 97.55%. Humacyte has a consensus price target of $8.00, indicating a potential upside of 6.95%. Given Humacyte's higher probable upside, research analysts plainly believe Evolv Technologies is more favorable than Humacyte.
66.7% of Evolv Technologies shares are owned by institutional investors. Comparatively, 44.7% of Humacyte shares are owned by institutional investors. 11.2% of Evolv Technologies shares are owned by company insiders. Comparatively, 23.1% of Humacyte shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
Humacyte received 7 more outperform votes than Evolv Technologies when rated by MarketBeat users. However, 83.33% of users gave Evolv Technologies an outperform vote while only 51.52% of users gave Humacyte an outperform vote.
Summary
Evolv Technologies beats Humacyte on 11 of the 17 factors compared between the two stocks.
Get Humacyte News Delivered to You Automatically
Sign up to receive the latest news and ratings for HUMA and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding HUMA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Humacyte Competitors List
Related Companies and Tools
